Acute Dyspnea After Use of Non-invasive Ventilation in COPD and Emphysema (Deventilation Syndrome)
Acquisition and Evaluation of Augemented Dyspnea After Use of Non-invasive Ventilation in Patients With COPD and Empysema (Deventilation Syndrome)
1 other identifier
observational
70
0 countries
N/A
Brief Summary
Acute dyspnea after use of non-invasive ventilation (NIV) is a common phenomenon in patients with COPD and emphysema. This trial aims to document incidence and severity of augmented dyspnea in patients with long term NIV therapy. These findings may help in understanding the pathomechanisms that lead to post-NIV dyspnea and thus give way to potential therapy schemes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Nov 2016
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 20, 2016
CompletedFirst Posted
Study publicly available on registry
October 21, 2016
CompletedStudy Start
First participant enrolled
November 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2018
CompletedOctober 21, 2016
October 1, 2016
11 months
October 20, 2016
October 20, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Incidence and severity of acute dyspnea after use of non-invasive Ventilation in COPD and emphysema
May 2018
Eligibility Criteria
Patients with chronic hypercapnic failure due to COPD III to IV GOLD and emphysema on long term noninvasive ventilation
You may qualify if:
- Males and females with stabile COPD, last exacerbation over one month,
- GOLD III to IV
- Regular use of noninvasive ventilation, more than four hours per day for more than one year
- Signed declaration of consent
- Sufficient language capabilities, german
You may not qualify if:
- Acute exacerbation in the past four weeks
- Acute pulmonary embolus
- Haemoptysis
- Severe neurological disease
- Severe cardiological disease
- Haemodynamic instability
- New hypoxia or worsening of hypercapnia more than twenty percent of usual rate
- Acute pneumothorax
- Other instable Situation, for example intraabdominal bleedings
- Drug or alcohol dependency
- Regular intake of morphium
- Adiposity BMI over 35
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Felix JF Herthlead
Study Officials
- PRINCIPAL INVESTIGATOR
Felix FJ Herth, Prof.
Medical Director Thoraxklinik Heidelberg
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Prof. Dr. med. Felix JF Herth
Study Record Dates
First Submitted
October 20, 2016
First Posted
October 21, 2016
Study Start
November 1, 2016
Primary Completion
October 1, 2017
Study Completion
May 1, 2018
Last Updated
October 21, 2016
Record last verified: 2016-10
Data Sharing
- IPD Sharing
- Will not share